ReviewIndian journal of microbiology2025
Nanotechnology-Based Modern Biosensors for the Detection of SARS-CoV-2 Virus.
Review in Indian journal of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of the COVID-19 pandemic has pointed out the urgent need for rapid and accurate diagnostic tools to detect the SARS-CoV-2 virus. Nanotechnology-based biosensors have emerged as a promising solution due to their high sensitivity, specificity, and speed in detecting biological molecules. This article focuses on the advancements in using nanotechnology for the development of modern biosensors tailored for the detection of the SARS-CoV-2 virus. Various nanomaterials, such as quantum dots, metallic nanoparticles, and nanowires, have been harnessed to enhance the performance of biosensors, offering improved detection limits and specificity. Besides this, innovative detection platforms, such as field-effect transistors, surface plasmon resonance, and electrochemical sensors, have revolutionized the landscape of SARS-CoV-2 diagnostics. These nanotechnology-based biosensors demonstrate the potential for point-of-care testing, enabling rapid and on-site detection with minimal sample preparation. The scalability, cost-effectiveness, and portability of these biosensors make them suitable for mass screening efforts in various healthcare settings, including hospitals, clinics, and community centers. The development of reliable biosensors for SARS-CoV-2 detection aligns with global efforts to curb the spread of the virus through early identification and containment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.